13-05-2025
Roth MKM Sticks to Its Buy Rating for Stereotaxis (STXS)
In a report released yesterday, Jason Wittes from Roth MKM reiterated a Buy rating on Stereotaxis (STXS – Research Report), with a price target of $5.00. The company's shares closed yesterday at $2.07.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Wittes covers the Healthcare sector, focusing on stocks such as Globus Medical, Allurion Technologies, and Monogram Orthopaedics Inc. According to TipRanks, Wittes has an average return of 2.7% and a 48.06% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stereotaxis with a $4.67 average price target, which is a 125.60% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target.
STXS market cap is currently $183.1M and has a P/E ratio of -7.17.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STXS in relation to earlier this year. Most recently, in March 2025, Isaac Paul J , a Director at STXS bought 38,000.00 shares for a total of $68,780.00.
